Daily FNArena News

A wrap of the day’s activity on the Australian stock market.

Moelis has taken a look at the portfolio of products waiting in the wings at Mayne Pharma and considers there is more upside for the stock.

Currently there’s pressure on laboratory services provider ALS but brokers are tuned to the potential upside.

Michael Gable of Fairmont Equities evaluates the technicals for WorleyParsons following the company’s shock profit warning and subsequent share price plunge.

As uranium miners across the globe defer or cut production, the uranium spot price has found some renewed hope.

A wrap of the day’s activity on the Australian stock market.

Brokers are somewhat divided over whether the pricing pressures Goodman Fielder is sustaining will hang around for the medium term.

OzForex has performed strongly since listing and brokers assess the opportunity for growth.

Nick Linton-Ffrost of Fifth Wave suggests a short-term trading idea on the ASX 200 index.

FNArena provides a weekly update of Australian listed corporate bond issues, current pricing and yield data.